Generic Medicine Info
Indications and Dosage
Type 2 diabetes mellitus
Adult: Initially, 100-250 mg daily as a single dose in the morning. Increase at wkly intervals by 100-250 mg if necessary. Maintenance: 250-500 mg daily. Doses >500 mg daily can be given in divided doses. Max: 1000 mg daily.
Elderly: Initial: 100 mg daily in the morning.
Special Patient Group
Malnourished patient: Initial: 100 mg daily in the morning.
Renal Impairment
Conservative initial and maintenance dosing.
Hepatic Impairment
Conservative initial and maintenance dosing.
Should be taken with food.
Hypersensitivity to tolazamide, sulfonylureas. Sole therapy in type 1 DM, diabetic ketoacidosis w/ or w/o coma, or other acute complications (e.g. major surgery, severe infection or trauma), uraemia.
Special Precautions
Patient w/ history of hepatic porphyria, G6PD deficiency. Elderly, debilitated and malnourished patients. Renal or hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Hypoglycaemia, nausea, vomiting, anorexia, intestinal gas, diarrhoea, constipation, cramps, wt gain, weakness, fatigue, lethargy, dizziness, vertigo, malaise, headache, urticaria, rash, photosensitivity reactions, hyponatraemia, syndrome of inappropriate secretion of antidiuretic hormone (SIADH), cholestatic jaundice, alterations in LFT results (e.g. bilirubin, cholesterol, AST, ALT). Rarely, leucopenia, thrombocytopenia, agranulocytosis, anaemia.
Patient Counseling Information
Adhere strictly to the prescribed diabetic diet.
Monitoring Parameters
Monitor blood glucose, glycosylated Hb level, signs and symptoms of hypoglycaemia.
Symptoms: Hypoglycaemia. Management: Mild hypoglycaemic symptoms w/o loss of consciousness or neurologic findings may be treated w/ oral glucose and adjustments in drug dosage and/or meal patterns. For hypoglycaemic coma, admin rapid IV inj of concentrated (50%) glucose soln followed by continuous infusion of a more dilute (10%) glucose soln.
Drug Interactions
Increased plasma concentration w/ certain antifungals (e.g. miconazole, fluconazole). NSAIDs and other highly protein-bound drugs (e.g. chloramphenicol, salicylates, sulfonamides, probenecid, coumarins, MAOIs, β-blockers) may potentiate hypoglycaemic action of tolazamide. Diminished therapeutic effect w/ thiazides, other diuretics, phenothiazines, corticosteroids, thyroid products, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers and isoniazid.
Food Interaction
May cause disulfiram-like reactions w/ alcohol.
Mechanism of Action: Tolazamide, a sulfonylurea antidiabetic agents that lowers blood glucose by stimulating the secretion of endogenous insulin from pancreatic β-cells.
Onset: 20 min.
Duration: 10-24 hr.
Absorption: Slowly but well absorbed from the GI tract. Time to peak plasma concentration: 4-8 hr.
Distribution: Plasma protein binding: 94%.
Metabolism: Extensively hepatic to 5 metabolites.
Excretion: Via urine (approx 85%) and faeces (7%). Half-life: Approx 7 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tolazamide, CID=5503, (accessed on Jan. 23, 2020)

Store between 20-25°C.
MIMS Class
Antidiabetic Agents
Anon. Tolazamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/08/2014.

Buckingham R (ed). Tolazamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 18/08/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Tolazamide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 18/08/2014.

Tolinase Tablet (Pharmacia and Upjohn Company). DailyMed. Source: U.S. National Library of Medicine. Accessed 18/08/2014.

Disclaimer: This information is independently developed by MIMS based on Tolazamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in